Skip to content

A longitudinal non-invasive study of changes in urinary bladder contractility secondary to benign prostatic hyperplasia.

A longitudinal non-invasive study of changes in urinary bladder contractility secondary to benign prostatic hyperplasia.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON29657
Enrollment
1020
Registered
2005-09-09
Start date
2001-11-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign prostatic hyperplasia (BPH)

Interventions

Sponsors

Dr. ir. R. van Mastrigt Dept. Urology, Urodynamics Erasmus MC P.O. Box 1738 3000 DR Rotterdam
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Men aged 38-77; 2. Mentally and physically able to complete a voiding diary and to visit the outpatient clinic; 3. Written informed consent to participate in the trial.

Exclusion criteria

Exclusion criteria: 1. Unable to urinate in a standing position; 2. Previous lower urinary tract surgery; 3. Congenital disease of the lower urinary tract; 4. Use of medication or other interventions for lower urinary tract symptoms; 5. Other diseases that could alter urinary function (e.g. Parkinson, CVA, DM, kidney failure, bladder/prostate cancer, current urinary tract infection); 6. Heart failure; 7. Voiding pattern at first visit incompatible with measurement technique, e.g. flow rate too low (<6 ml/s), interrupted voiding, straining; 8. Mentally or physically unable to complete a voiding diary and to visit the outpatient clinic; 9. Use anticoagulants.

Design outcomes

Primary

MeasureTime frame
The study is observational, there is no endpoint.

Contacts

Public ContactR. Mastrigt, van

Erasmus Medical Center, Josephine Nefkens Institute, Department of Urology, Urodynamics, P.O. Box 1738

r.vanmastrigt@erasmusmc.nl+31 (0)10 4088058

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)